CTLA4 and non-small cell lung carcinoma: NCT03581487 is a phase I/II trial analyzing the best dose of selumetinib (MEK inhibitor) in combination with durvalumab (anti-PD-L1 antibody) and tremelimumab (CTLA-4-Ab) for the treatment of patients with stage IV or recurrent NSCLC [38].